Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

Eli Lilly said Wednesday that its weight-loss medication Zepbound (tirzepatide) demonstrated superior efficacy over Novo ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in ...

The battle between the two front runners in the vast weight loss released top-line results from the SURMOUNT-5 Phase IIIb ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which ...

The study was designed to evaluate Zepbound compared with Novo Nordisk's Wegovy in adults with obesity with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep ...

Eli Lilly's obesity drug Zepbound showed 47% more weight loss than Novo Nordisk's Wegovy in a major comparative trial. The ...

Kara Kennedy's husband was a yo-yo dieter for decades, until he discovered Zepbound – an Ozempic-like drug – and lost 3.5 ...